The successful completion of Phase I of the world’s first clinical trial investigating the use of DMT-assisted therapy could lay the foundation for a “new paradigm”...
Atai Life Sciences and Introspect Digital Therapeutics will be testing a novel, digital therapeutic approach for patients using ketamine for treatment resistant depression.
Mindset Pharma says its next-generation psilocybin compounds could change the paradigm of microdosing by limiting the psychedelic effect.
Diamond Therapeutics has received approval from Health Canada to carry out a clinical trial for the treatment of mental health conditions with low-dose psilocybin.
Salvinorin A, derived from the plant Salvia divinorum, is to be researched as a treatment for mental health conditions.